Asston Pharmaceuticals (APL) Share Price Falls 8.46% to Rs 114: What Today’s Decline Shows
- September 1, 2026
- Posted by: Harsh Piplani
- Category: News
Asston Pharmaceuticals Share Price fell to Rs 114 on 01 September 2026, down 8.46% for the day. The move reduced the company’s market capitalisation to Rs 106.01 crore. The Micro Cap healthcare stock opened at Rs 126.1, touched an intraday high of Rs 126.1 and later declined to Rs 114, which was also the session low at the time of this update.
The supplied data confirms a sharp single-session decline, but it does not establish any company-specific reason behind the move. What is available is still useful: turnover stood at Rs 1.31 crore, the stock finished near the bottom of its intraday range, and the broader fundamental picture shows moderate valuation multiples alongside strong reported return ratios.
That is why Asston Pharmaceuticals Share Price is drawing attention today. When a small-cap pharma stock records a notable fall while still screening with relatively solid profitability metrics, investors usually look beyond the day’s move and compare valuation, peer positioning and industry context. This article stays strictly with the verified numbers provided.
Asston Pharmaceuticals (APL) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 114 |
| Previous Close | Rs 124.54 |
| Today's Move | -Rs 10.54 (-8.46%) |
| Open | Rs 126.1 |
| High | Rs 126.1 |
| Low | Rs 114 |
| Turnover | Rs 1.31 crore |
| Market Capitalisation | Rs 106.01 crore |
| Market Cap Category | Micro Cap |
From an intraday perspective, the pattern was weak. The stock opened above the previous close, but the opening price of Rs 126.1 also became the day’s high. From there, it moved lower through the session and ended at Rs 114, matching the intraday low. That kind of price structure usually indicates that sellers remained in control for most of the day.
In absolute terms, the stock was down Rs 10.54 from the previous close of Rs 124.54. Turnover of Rs 1.31 crore suggests the move came with visible trading activity. Because the company is classified as a Micro Cap, day-to-day swings can look sharper than they might in larger, more liquid names. For that reason, Asston Pharmaceuticals Share Price is best viewed not only through one session’s decline but also through its valuation and operating metrics.
Asston Pharmaceuticals (APL) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 106.01 crore |
| P/E Ratio | 27.44x |
| P/B Ratio | 2.77x |
| ROE | 50.56% |
| ROCE | 42.64% |
| EPS | Rs 4.54 |
| Book Value Per Share | Rs 44.97 |
| Dividend Yield | 0% |
The fundamental snapshot is notable for two reasons. First, the stock is not priced at an extreme multiple on the supplied numbers. At Rs 114, it trades at a P/E of 27.44 and a P/B of 2.77. EPS is Rs 4.54 and book value per share is Rs 44.97. Dividend yield is 0%, so the stock is not currently reflected as a cash-yield story in the data provided.
Second, the profitability ratios are strong on the face of the reported figures. ROE stands at 50.56% and ROCE at 42.64%. Those are high readings for any listed company and are especially important here because they contrast with a day when the stock price fell sharply. Put simply, the available data shows a stock under pressure in the market, but not one that screens weak on return ratios.
Technical reference points add one more layer. The latest RSI is 67.34, while the stock remains above both its 50-day moving average of 82.26 and 200-day moving average of 81.37. Those figures do not explain the day’s move, but they do show that the current price is still above the two longer moving-average markers supplied.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 27.44x |
| Benchmark Median P/E | 30.92x |
| Benchmark Average P/E | 48.02x |
| Benchmark P/E Range | 3.87x to 667.16x |
| Company P/B Ratio | 2.77x |
| Benchmark Median P/B | 2.88x |
| Benchmark Average P/B | 4.34x |
| Company ROE | 50.56% |
| Benchmark Median ROE | 11.81% |
| Benchmark Average ROE | 11.21% |
| Company ROCE | 42.64% |
| Benchmark Median ROCE | 13.65% |
| Benchmark Average ROCE | 13.76% |
| Company Market Capitalisation | Rs 106.01 crore |
| Benchmark Median Market Cap | Rs 683.05 crore |
| Benchmark Average Market Cap | Rs 14,252.9 crore |
Asston Pharmaceuticals operates in the Healthcare sector under Pharmaceuticals & Drugs. The benchmark covers 201 companies in the same industry, which gives a useful basis for context. On valuation, the company’s P/E of 27.44 is below the industry median of 30.92 and below the average of 48.02. On P/B, its 2.77 is slightly below the median of 2.88 and below the average of 4.34.
The benchmark ranges also show how wide dispersion can be in pharma. Industry P/E values run from 3.87 to 667.16 across 168 companies, while P/B ranges from -11.1 to 27.39 across 199 companies. Against that backdrop, Asston’s multiples sit closer to the middle than the upper end.
The profitability comparison is more striking. ROE of 50.56% is well above the industry median of 11.81% and average of 11.21. ROCE of 42.64% is also far above the median of 13.65% and average of 13.76. The main area where the company looks smaller than the industry norm is size: its market capitalisation of Rs 106.01 crore is below the benchmark median of Rs 683.05 crore and far below the average of Rs 14,252.9 crore. In short, Asston Pharmaceuticals Share Price is tied to a company that looks small by size, moderate on valuation and strong on reported returns.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,60,696.31 | 38.8 | 5.43 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,46,062.83 | 83.91 | 13.89 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,91,515.22 | 86.82 | 21.1 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,18,403.7 | 25.69 | 4.3 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,14,554.33 | 33.94 | 3.25 | 11.83 | 16 |
The supplied peer set underlines how small Asston is versus major pharmaceutical names. Its market capitalisation of Rs 106.01 crore is far below Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla, all of which have market values above Rs 1,14,000 crore in the dataset.
On valuation, Asston’s P/E of 27.44 is below Sun Pharma’s 38.8, Divi’s 83.91, Torrent’s 86.82 and Cipla’s 33.94, while slightly above Zydus Lifesciences at 25.69. Its P/B of 2.77 is also below Sun Pharma’s 5.43, Divi’s 13.89, Torrent’s 21.1 and Cipla’s 3.25, and below Zydus at 4.3.
Profitability is where the contrast is strongest. Asston’s ROE of 50.56% is above all five supplied peers, and its ROCE of 42.64% is also higher than each of them. That does not explain today’s decline, but it does show why the stock remains interesting despite the fall: on the reported numbers, its returns stand out more than its valuation multiples do.
Why Investors Are Watching This Stock
- Asston Pharmaceuticals Share Price declined 8.46% to Rs 114 from Rs 124.54.
- The stock opened at Rs 126.1, made that its day’s high, and then fell to Rs 114.
- Turnover was Rs 1.31 crore, showing active trading.
- P/E of 27.44 and P/B of 2.77 sit below industry averages of 48.02 and 4.34.
- ROE of 50.56% and ROCE of 42.64% are well above industry medians.
- Current price remains above the 50 DMA of 82.26 and 200 DMA of 81.37.
About Asston Pharmaceuticals
Asston Pharmaceuticals belongs to the Healthcare sector and operates in Pharmaceuticals & Drugs. Based on the supplied context, it is a listed Micro Cap company with a market capitalisation of Rs 106.01 crore. In sector terms, that makes it much smaller than the large branded peers referenced above, even though some of its profitability ratios compare favourably on the available data.
Track Asston Pharmaceuticals Share Price on Univest
Use Asston Pharmaceuticals (APL) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
Investors tracking Asston Pharmaceuticals Share Price can use Univest to compare live price action with valuation ratios, moving averages, peer metrics and industry benchmarks in one place. That can help separate a one-day move from the company’s wider market context.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Asston Pharmaceuticals Share Price falling today?
Ans. The stock fell 8.46% to Rs 114 from the previous close of Rs 124.54. The supplied data confirms the decline and weak intraday structure, but it does not provide any verified company-specific trigger.
What is Asston Pharmaceuticals Share Price today?
Ans. Asston Pharmaceuticals Share Price was Rs 114 at the time of this update. The session range was Rs 126.1 on the high side and Rs 114 on the low side.
How much did the stock decline today?
Ans. It was down Rs 10.54 in absolute terms, which equals a decline of 8.46% for the day. The previous close was Rs 124.54. The stock moved 8.46% lower during the session.
What are the key valuation metrics?
Ans. The supplied figures show a P/E ratio of 27.44, a P/B ratio of 2.77, EPS of Rs 4.54, book value per share of Rs 44.97 and dividend yield of 0%.
How does the company compare with the pharma industry benchmark?
Ans. Its P/E of 27.44 is below the industry median of 30.92 and average of 48.02. Its P/B of 2.77 is also slightly below the industry median of 2.88 and below the average of 4.34.
Are the return ratios strong?
Ans. On the supplied data, yes. ROE is 50.56% and ROCE is 42.64%, both well above the industry medians of 11.81% and 13.65%. ROE stands at 50.56%. ROCE stands at 42.64%.
How does it compare with major listed peers?
Ans. It is far smaller by market value than Sun Pharma, Divi’s, Torrent, Zydus and Cipla. However, its reported ROE and ROCE are higher than each of those supplied peers. Comparable listed companies include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals.
